Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).
Publication
, Conference
Hensing, TA; Wang, XF; Gao, J; Stinchcombe, T; Knopp, MV; Dudek, AZ; Graziano, SL; Patel, JD; Faller, B; Dragnev, KH; Kozono, DE; Vokes, EE
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2019
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2019
Volume
37
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hensing, T. A., Wang, X. F., Gao, J., Stinchcombe, T., Knopp, M. V., Dudek, A. Z., … Vokes, E. E. (2019). Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 37). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Hensing, Thomas A., Xiaofei F. Wang, Junheng Gao, Tom Stinchcombe, Michael V. Knopp, Arkadiusz Z. Dudek, Stephen L. Graziano, et al. “Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
Hensing TA, Wang XF, Gao J, Stinchcombe T, Knopp MV, Dudek AZ, et al. Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.
Hensing, Thomas A., et al. “Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).” JOURNAL OF CLINICAL ONCOLOGY, vol. 37, no. 15, AMER SOC CLINICAL ONCOLOGY, 2019.
Hensing TA, Wang XF, Gao J, Stinchcombe T, Knopp MV, Dudek AZ, Graziano SL, Patel JD, Faller B, Dragnev KH, Kozono DE, Vokes EE. Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2019
Volume
37
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences